Ozempic Lawsuit: Seeking Justice for Gastroparesis Victims
If you or someone you love has been harmed by the medication Ozempic, you may be entitled to significant compensation. We are now exclusively accepting cases involving gastroparesis, a debilitating condition often linked to Ozempic use. Gastroparesis, characterized by delayed stomach emptying, can lead to symptoms such as severe nausea, vomiting, and nutritional deficiencies.
To qualify, your diagnosis must be supported by a gastric emptying study, confirming this serious injury.
Our team is committed to ensuring that you receive the justice and relief you deserve, helping you navigate the complex legal process with confidence and understanding.
Discuss Your Legal Options for Filing an Ozempic Lawsuit
Are you considering filing an Ozempic lawsuit due to severe health complications? Ongoing lawsuits involving Ozempic have brought attention to its potential risks, particularly serious gastrointestinal side effects like gastroparesis, stomach paralysis, delayed gastric emptying, bowel obstruction, and severe vomiting. These alleged injuries have led to significant medical expenses and emergency medical treatment for many users. If you’ve suffered after taking Ozempic, you may be eligible to join the ongoing Ozempic multidistrict litigation (MDL).
Ozempic, a diabetes drug widely prescribed for diabetes management and weight loss, has become the center of mass tort litigation in the United States. Plaintiffs argue that drug manufacturers Novo Nordisk and Eli Lilly failed to adequately warn patients and consumers about the potential risks of the drug, including severe gastrointestinal issues and significant health complications. These claims form the basis of numerous Ozempic lawsuits filed in courts like the Pennsylvania federal court and the Eastern District of the United States District Court.
In these lawsuits, plaintiffs argue that the pharmaceutical companies responsible for Ozempic and similar drugs, including other weight loss medications, neglected their duty to provide sufficient warnings about delayed stomach emptying and other serious side effects observed during clinical trials. These lawsuits claim that users prescribed Ozempic for diabetes management or weight management were not adequately informed of potential risks like gastrointestinal injuries or the need for emergency medical treatment, resulting in ongoing suffering and significant incurred medical expenses.
If you or a loved one experienced severe abdominal pain, stomach paralysis, or other serious complications after taking the diabetes medication Ozempic, it is essential to act now. Ozempic users filing lawsuits often cite the failure of Novo Nordisk and Eli Lilly to adequately warn consumers, leading to alleged injuries and long-term health complications. Many cases are being centralized as Ozempic multidistrict litigation, with a judicial panel overseeing these lawsuits.
At Rueb Stoller Daniel, our dedicated Ozempic attorneys and mass tort litigation experts are here to guide you. As experienced Ozempic lawyers, we have represented plaintiffs in lawsuits against pharmaceutical companies for dangerous drugs. Our law firm offers a free case evaluation to help you determine if you qualify for compensation.
Don’t wait—contact us today for a free consultation and take the first step in your Ozempic litigation journey. Let our plaintiffs’ lawyers help you hold drug manufacturers accountable for their failure to warn consumers. Call us now at 1-866-CALL-RSD to discuss your legal options and join the ongoing Ozempic lawsuit to reclaim your health and financial security.
Significant Surge in Lawsuits Filed Against Novo Nordisk at the Start of 2025
The number of lawsuits filed against Novo Nordisk, the manufacturer of the diabetes drug Ozempic, has experienced a significant uptick, reflecting the growing concern among patients and legal experts regarding the drug’s safety. As of March 10, 2025, there are 1,521 active lawsuits consolidated in the federal multidistrict litigation (MDL).
The rising number of lawsuits highlights the widespread claims by individuals who allege that their use of Ozempic resulted in severe health complications, including delayed gastric emptying, stomach paralysis, severe gastrointestinal issues, and other significant injuries. Many of these plaintiffs argue that Novo Nordisk failed to adequately warn users of the drug’s potential risks, particularly in relation to its off-label use for weight loss, which has become increasingly popular.
This growing body of litigation represents individuals from across the United States, with cases originating in states such as Pennsylvania, California, and Florida. These plaintiffs are seeking compensation for alleged injuries, medical expenses, lost wages, and pain and suffering. Many of these cases also point to the lack of sufficient warnings on Ozempic’s labeling, which they claim downplayed or omitted critical safety information about side effects like gastroparesis and severe vomiting.
The increase in lawsuits also reflects a broader trend in litigation involving GLP-1 receptor agonists, a class of drugs that includes Ozempic. Legal experts suggest that the continued growth in the number of cases may be influenced by heightened awareness through media coverage, as well as recent FDA updates to the drug’s warning labels. Additionally, law firms across the country are actively seeking to represent affected individuals, offering free consultations to those who may be eligible to join the lawsuits.
The federal MDL, which centralizes these cases for pretrial proceedings, aims to streamline the litigation process and address common legal and factual questions among the claims. As the number of cases rises, the litigation is expected to expand further, potentially becoming one of the largest mass torts involving diabetes and weight loss medications in recent years.
The increase in filed lawsuits not only underscores the serious concerns surrounding Ozempic’s safety profile but also reflects a growing push for accountability from pharmaceutical companies like Novo Nordisk. For affected individuals, this development represents a critical opportunity to seek justice and compensation for their alleged injuries.
2025 Ozempic Lawsuit Updates
- April 10, 2025:Eli Lilly and Novo Nordisk are asking the court to block two expert witnesses who link drugs like Ozempic and Mounjaro to gastroparesis. They argue that without a specific test—a gastric emptying study—any expert opinion should be excluded, claiming symptoms and timing alone aren’t scientifically reliable.This move could disqualify many claims from plaintiffs who didn’t undergo formal testing because their symptoms improved after stopping the medication, and their doctors didn’t see the need for further evaluation. Critics say the drugmakers are trying to dismiss valid cases by imposing unrealistic standards that don’t reflect how medicine is actually practiced.
- April 1, 2025: In March, 164 additional lawsuits were filed in the Ozempic multidistrict litigation, building on February’s 110 new cases and raising the total to 1,685. The increase comes as both sides gear up for an important Rule 702 hearing scheduled for May 14, 2025. At issue is whether expert opinions on causation will be deemed admissible—a decision that could significantly impact which claims are allowed to move forward as the litigation progresses.
- March 16, 2025: Eli Lilly has filed a motion urging the court to require that a gastroparesis diagnosis be based on objective, contemporaneous testing. The motion also seeks to bar testimony from plaintiffs’ experts who argue that a diagnosis can be valid without such testing. Eli Lilly claims this requirement is necessary to maintain medical reliability and prevent speculative diagnoses that could weaken the case’s scientific foundation. However, this move aligns with the company’s broader strategy to limit the number of claims. By tightening the criteria for valid diagnoses, fewer plaintiffs will be able to move forward, making this motion less about medical accuracy and more about restricting accountability.
- March 5, 2025: Ozempic MDL Sees 78 New Cases in February. The Ozempic multidistrict litigation (MDL) continues to expand, with 78 new cases filed in February 2025. Although this is a slight drop compared to the 110 cases added in January, the steady flow of lawsuits suggests a consistent trend that may continue in the coming months. With these latest additions, the total number of pending cases has now reached 1,521, reflecting growing concerns and legal action tied to the medication.
- February 5, 2025: Following a slow December with just 31 new cases, the GLP-1 Receptor MDL saw a significant rise in January, with 110 new lawsuits filed. This brings the total number of pending cases to 1,443.
- February 2, 2025: A Michigan woman has filed a lawsuit against Novo Nordisk, claiming that the company’s popular drug, Ozempic, caused her to experience severe gastrointestinal damage. The legal action, originally intended for the Western District of Texas, was filed in Pennsylvania due to the ongoing MDL. The suit accuses Novo Nordisk of negligence in designing and marketing Ozempic, failing to adequately warn patients about serious risks such as gastroparesis, ileus, and intestinal blockages.
- January 11, 2025: A crucial Rule 702 evidentiary hearing has been set for May 14, 2025, to address Cross-Cutting Issue No. 1 in the litigation. The hearing will focus on the admissibility of expert testimony under Rule 702, deciding whether the opinions of specific experts can be included in the case. All plaintiffs’ experts on causation, who are under motion to exclude, will testify.
- January 2, 2025: The Ozempic MDL saw a modest increase last month, with 31 new cases filed. This brings the total number of pending cases to 1,331.
- December 21, 2024: The Judicial Panel on Multidistrict Litigation has decided to broaden the GLP-1 receptor agonist MDL to incorporate claims related to Novo Nordisk’s Saxenda. However, it declined to include cases involving blood clot injuries, such as deep vein thrombosis and pulmonary embolism, citing concerns about added complexity.
- December 3, 2024:In November, the Ozempic MDL saw 79 new filings, adding to over 200 cases submitted in the last two months. The total number of pending cases has now reached 1,300.
- November 15, 2024: A Tennessee woman has filed a new lawsuit within the national MDL for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Philadelphia. She claims that Novo Nordisk’s drugs, Ozempic and Wegovy, caused her to suffer from severe, chronic gastrointestinal injuries, including gastroparesis.
- November 5, 2024: As the litigation moves forward, gastric emptying studies are expected to become a crucial method for supporting claims that medications like Ozempic can affect gastrointestinal motility. Introducing results from these studies in court offers scientific evidence, helping to differentiate legitimate cases of gastroparesis from other digestive disorders.
- November 1, 2024: In October, 131 new cases were added, raising the total number of pending lawsuits to 1,221.
- October 19, 2024: A lawsuit filed by a plaintiff from DeRidder, Louisiana, claims serious health complications from Ozempic, including gastroparesis, which led to stomach paralysis. The plaintiff had to undergo multiple treatments to manage her symptoms, which have had a lasting impact on her daily activities and overall health.
- October 1, 2024: The Ozempic class action MDL is expanding, with over 300 cases added in August and an additional 101 cases in September, bringing the total to 1,090. This rapid increase underscores the widespread impact of Ozempic on users across the country and the urgent need for accountability.
- September 17, 2024: Ozempic lawyers have outlined key topics for next week’s status conference, focusing on discovery procedures and motions. These discussions will set the groundwork for how evidence will be gathered and presented as the case moves forward.
- September 5, 2024: A lawsuit filed in Kentucky claims a user developed gastroparesis after taking Ozempic from January to April 2023. The plaintiff’s symptoms have significantly affected her quality of life, leading to multiple hospitalizations and ongoing treatment.
- September 3, 2024: MDL-3094 now has 869 active lawsuits, a 151% increase since August 1. The rising number of cases reflects growing awareness and concern regarding the potential dangers of Ozempic use.
- August 2024: A status conference is set for August 8 to discuss key issues, including Plaintiff Fact Sheets, the discovery process, and planning for Science Day. Science Day will involve presentations by medical experts to educate the court on the medical complexities associated with Ozempic.
- July 2024: In July 2024, there were only four new cases filed, bringing the total number of active lawsuits to 105. Although fewer cases were filed this month, the severity of reported injuries remains a serious concern.
- June 2024: Judge Karen Marston in Philadelphia is overseeing the litigation involving Ozempic and similar drugs. Plaintiffs expect the litigation to encompass over 10,000 lawsuits as more individuals come forward, reporting adverse health effects.
- May 2024: Recent settlements involve pharmacies distributing unapproved compounded versions of semaglutide, including Ozempic. These settlements highlight concerns around the unauthorized sale and distribution of these drugs, which may pose additional health risks.
- April 2024: Novo Nordisk is actively pursuing litigation against pharmacies distributing unauthorized compounded forms of Ozempic. The company argues that these compounded versions may lack quality control, potentially increasing the risk of harm.
- March 2024: The first status conference for the class action lawsuit was scheduled for March 14, 2024, signaling increased momentum. This conference provided an initial opportunity for both sides to present their perspectives and begin setting the litigation timeline.
- January 2024: The FDA is assessing cases of hair loss, suicidal thoughts, and aspiration during sedation related to Ozempic use. These additional side effects add to the growing list of safety concerns associated with this medication.
What is the Ozempic Lawsuit About?
The Ozempic lawsuit aims to seek justice for those harmed by the medication. Not all adverse effects qualify, but if you used Ozempic before March 2022 and experienced gastroparesis confirmed by a gastric emptying study, you might be eligible to file a lawsuit.
Gastroparesis is a condition that prevents the stomach from properly emptying, leading to severe symptoms like chronic nausea, vomiting, bloating, and malnutrition. These symptoms can greatly reduce a person’s ability to live a normal life, often requiring ongoing medical intervention. If you are suffering from this condition after using Ozempic, you may have legal grounds for compensation.
Common Claims Include:
- Insufficient warnings provided by the manufacturer, which failed to adequately communicate the risks of gastroparesis and related complications.
- Defective manufacturing or labeling that directly led to injuries and misled consumers about the safety of the medication.
- Misleading safety or efficacy guarantees by the manufacturer, causing patients to use Ozempic without fully understanding its potential risks.
Consult a skilled mass tort attorney to evaluate your case and determine whether you meet the qualifications for filing a lawsuit. Our legal experts will help you navigate this complex process and fight for the justice you deserve.
Potential Compensation
By filing an Ozempic lawsuit, you may be entitled to compensation for a variety of damages, including:
- Medical expenses: Covering costs for past, current, and future medical treatments related to gastroparesis, including hospital stays, medications, surgeries, and other interventions.
- Pain and suffering: Compensation for the physical pain and emotional suffering caused by your condition, which can significantly affect your quality of life.
- Lost wages: Reimbursement for income lost due to your inability to work while undergoing treatment and managing your symptoms.
- Emotional distress: Compensation for the psychological impact of living with a chronic, debilitating condition like gastroparesis, which can lead to anxiety, depression, and other emotional challenges.
Our attorneys will assess your situation to determine the extent of your potential compensation, taking into account all the factors that have impacted your life.
Criteria for Joining the Semaglutide/Ozempic Gastroparesis Lawsuit
Rueb Stoller Daniels Law Firm is committed to helping individuals who have experienced severe injuries due to the use of Semaglutide or Ozempic. To be represented in this lawsuit, potential clients must meet specific criteria to ensure their case aligns with the legal and medical standards required for a successful claim.
Eligibility Requirements
To qualify for representation by Rueb Stoller Daniels in the Semaglutide/Ozempic lawsuit, you must meet the following criteria:
- Confirmed Use of Semaglutide or Ozempic
You must have been prescribed and used Semaglutide or Ozempic, medications commonly marketed for the treatment of Type 2 diabetes and weight management. - Diagnosis of Gastroparesis
You must have been diagnosed with gastroparesis, a condition characterized by delayed gastric emptying, which has been linked to the use of these medications. - Diagnosis Supported by a Gastric Emptying Study
A gastric emptying study must confirm your gastroparesis diagnosis. This diagnostic test measures how quickly food moves from your stomach into your intestines, providing definitive evidence of the condition. - Experienced Symptoms of Gastroparesis
Symptoms associated with gastroparesis may include chronic nausea, vomiting, abdominal pain, bloating, early satiety, and severe disruptions to your daily life. These symptoms must be attributable to your use of Semaglutide or Ozempic. - Evidence of Injury or Harm
You must have experienced significant harm or injury resulting from gastroparesis, such as the need for ongoing medical treatment, loss of quality of life, or other damages.
Why These Criteria Are Important
These eligibility requirements are necessary to ensure your claim meets the legal and evidentiary standards needed to build a strong case. Rueb Stoller Daniels works with medical professionals and legal experts to analyze your case, determine its merit, and seek the justice and compensation you deserve.
Contact Us to Evaluate Your Case
If you meet the above criteria, we encourage you to reach out to Rueb Stoller Daniels for a free case evaluation. Our experienced legal team is ready to discuss your situation, review your medical records, and guide you through the process of joining the lawsuit. Take the first step toward holding the manufacturers of Semaglutide and Ozempic accountable for their negligence. Contact us today at 1-866-CALL-RSD
How to File an Ozempic Lawsuit
Understanding how to file an Ozempic lawsuit may seem daunting, but Rueb Stoller Daniel is here to guide you. Our team will work closely with you to ensure that your rights are protected throughout the entire legal process. Here’s how we can help:
- Evaluate your case during a free consultation to determine if you qualify.
- Gather evidence, including your medical records, healthcare provider testimonies, and other documentation needed to support your case.
- Ensure your lawsuit is filed within applicable statutes of limitations, which is crucial to maintaining your eligibility for compensation.
- Engage in negotiations for a fair settlement that reflects the full extent of your damages.
- Prepare your case for trial if a settlement cannot be reached, ensuring you have strong representation in court.
We understand that this process can feel overwhelming, especially while dealing with medical challenges. Our compassionate team is dedicated to making this process as smooth as possible, offering support and guidance every step of the way.
What is Ozempic?
Ozempic, also known by its generic name semaglutide, is an injectable prescription medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes.
It belongs to a class of drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists, which work by stimulating insulin production and lowering blood sugar levels.
Despite being officially approved solely for the treatment of diabetes, Ozempic has gained significant attention and popularity due to its ability to treat obesity and aid in weight loss.
How It Works
Ozempic works by stimulating the release of insulin, a hormone responsible for regulating blood sugar levels. By activating GLP-1 receptors, it assists the body in managing glucose and curbing appetite. However, despite its intended benefits, Ozempic has been associated with a range of potential side effects.
Side Effects of Ozempic
Ozempic has shown efficacy in managing blood sugar, but potential side effects include:
- Gastrointestinal symptoms: Nausea, vomiting, diarrhea, and constipation are commonly reported side effects, which can range from mild to severe.
- Gastroparesis (stomach paralysis): A more serious side effect linked to Ozempic, gastroparesis results in delayed stomach emptying, which can cause persistent nausea, vomiting, and other serious health issues.
Gastroparesis and Gastrointestinal Issues
Recent studies link Ozempic to increased risks of gastroparesis, particularly when used at higher doses or for weight loss purposes. Gastroparesis can lead to significant health complications, such as severe malnutrition, dehydration, and a reduced ability to manage everyday activities. Often, patients with gastroparesis require frequent medical attention, including hospitalizations and specialized treatments.
It’s crucial for patients and healthcare providers to understand these risks before starting treatment with Ozempic. If you were not adequately warned about these risks, you may have a valid legal claim.
Recent findings show there may be dangers with injectable medications that have semaglutide (like Ozempic) because they can cause problems in the intestines. If someone ends up in the hospital or dies because of these issues, they may be eligible for financial compensation for medical bills and pain and suffering.
These drugs can make the stomach digest food more slowly. Sometimes, this can cause serious stomach pain, leading to a condition called “gastroparesis” or stomach paralysis.
On August 2, a woman named Jaclyn Bjorklund, who is 44 and lives in Louisiana, started a lawsuit. She lost 150 pounds with her doctor’s help using these drugs but says they caused her to have stomach paralysis.
Her lawyers stress that these problems could affect her for the rest of her life. She’s mainly suing the big drug company Novo Nordisk (who makes Ozempic) because they didn’t warn people about the chance of major stomach issues.
Helpful Resources on Ozempic Lawsuits and Side Effects
If you or a loved one has been affected by Ozempic and are seeking more information, the following resources provide valuable insight into the ongoing lawsuits, potential side effects, and the legal options available to you.
Understanding Ozempic Side Effects and Linked Diseases
Ozempic has been linked to a number of serious side effects and health risks. If you are concerned about how Ozempic may have impacted your health, explore our comprehensive overview of Side Effects of Ozempic and Linked Diseases to learn more.
Get in Touch with an Experienced Mass Tort Lawyer
If you or a loved one have been harmed by Ozempic, Rueb Stoller Daniel Law Firm is here to stand by your side. We understand the physical, emotional, and financial toll that gastroparesis can take, and we are committed to holding the manufacturers accountable for their negligence.
Contact us at 1-866-CALL-RSD to schedule your free consultation and initiate your Ozempic lawsuit today.
Our dedicated team of experienced attorneys will evaluate your case, answer your questions, and provide you with the support you need to pursue justice and secure the compensation you deserve.
Let us help you take the next steps towards recovery and resolution.
